BlackRock’s Fusion Pharmaceuticals Inc. Common Shares FUSN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-516,795
| Closed | -$11M | – | 5391 |
|
|
2024
Q1 | $11M | Buy |
516,795
+96,989
| +23% | +$1.16M | ﹤0.01% | 3302 |
|
|
2023
Q4 | $4.03M | Buy |
419,806
+411,553
| +4,987% | +$2M | ﹤0.01% | 3776 |
|
|
2023
Q3 | $21.5K | Hold |
8,253
| – | – | ﹤0.01% | 5131 |
|
|
2023
Q2 | $38.5K | Hold |
8,253
| – | – | ﹤0.01% | 5110 |
|
|
2023
Q1 | $31.1K | Hold |
8,253
| – | – | ﹤0.01% | 5191 |
|
|
2022
Q4 | $26K | Hold |
8,253
| – | – | ﹤0.01% | 5345 |
|
|
2022
Q3 | $25K | Hold |
8,253
| – | – | ﹤0.01% | 5477 |
|
|
2022
Q2 | $20K | Hold |
8,253
| – | – | ﹤0.01% | 5558 |
|
|
2022
Q1 | $64K | Sell |
8,253
-1,300
| -14% | -$9.43K | ﹤0.01% | 5376 |
|
|
2021
Q4 | $40K | Sell |
9,553
-404,703
| -98% | -$2.52M | ﹤0.01% | 5444 |
|
|
2021
Q3 | $3.28M | Sell |
414,256
-56,047
| -12% | -$472K | ﹤0.01% | 4117 |
|
|
2021
Q2 | $3.8M | Sell |
470,303
-337,233
| -42% | -$2.9M | ﹤0.01% | 3996 |
|
|
2021
Q1 | $8.66M | Sell |
807,536
-23,201
| -3% | -$271K | ﹤0.01% | 3665 |
|
|
2020
Q4 | $9.76M | Buy |
830,737
+370,819
| +81% | +$4.66M | ﹤0.01% | 3375 |
|
|
2020
Q3 | $5.53M | Buy |
459,918
+6,727
| +1% | +$91.9K | ﹤0.01% | 3529 |
|
|
2020
Q2 | $7.92M | Buy |
+453,191
| New | +$7.89M | ﹤0.01% | 3317 |
|
BlackRock's FUSN Position: Q2 2024 in Review
BlackRock sold out of Fusion Pharmaceuticals Inc. Common Shares (FUSN) in Q2 2024, closing a stake of 516,795 shares — an estimated $11M sold.
BlackRock first reported a position in FUSN in Q2 2020 and held it in 16 quarters. The position peaked at $11M in Q1 2024. 0 funds tracked by Wall St. Rank hold FUSN as of Q2 2024.
- BlackRock reported no remaining Fusion Pharmaceuticals Inc. Common Shares position as of Q2 2024 after selling out during the quarter.
- BlackRock sold 516,795 Fusion Pharmaceuticals Inc. Common Shares shares in Q2 2024, an estimated $11M.
- BlackRock first reported a position in Fusion Pharmaceuticals Inc. Common Shares in Q2 2020 and held it in 16 quarters.
- BlackRock's Fusion Pharmaceuticals Inc. Common Shares position peaked at $11M in Q1 2024.
- 0 funds tracked by Wall St. Rank held Fusion Pharmaceuticals Inc. Common Shares as of Q2 2024.
Based on BlackRock's 13F filing for Q2 2024, filed 13 Aug 2024.